Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: a pathway-based analytical study
R Parit, S Jayavel - European journal of pharmacology, 2021 - Elsevier
Abstract Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) outbreak is a
major public health concern, which has accounted for> 1.7 million deaths across the world …
major public health concern, which has accounted for> 1.7 million deaths across the world …
Association of ACE2 receptor and ACEIs/ARBs with disease severity in COVID-19
S Sinha, A Sehgal, R Sehgal - Drug Discoveries & Therapeutics, 2020 - jstage.jst.go.jp
Coronavirus disease 2019 (COVID-19) is found to be associated with various comorbidities
which include cardiovascular diseases, hypertension, and diabetes. The impaired regulation …
which include cardiovascular diseases, hypertension, and diabetes. The impaired regulation …
Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention
E Shirbhate, J Pandey, VK Patel, M Kamal… - Pharmacological …, 2021 - Springer
Angiotensin-converting enzyme (ACE) and its homologue, ACE2, are commonly allied with
hypertension, renin–angiotensin–aldosterone system pathway, and other cardiovascular …
hypertension, renin–angiotensin–aldosterone system pathway, and other cardiovascular …
ACE2 as a potential therapeutic target for pandemic COVID-19
B Chatterjee, SS Thakur - RSC advances, 2020 - pubs.rsc.org
SARS-CoV-2 virus invades the host through angiotensin-converting enzyme 2 (ACE2)
receptors by decreasing the ACE2 expression of the host. This disturbs the dynamic …
receptors by decreasing the ACE2 expression of the host. This disturbs the dynamic …
Association of COVID-19 with comorbidities: An update
S Chatterjee, LV Nalla, M Sharma… - ACS Pharmacology & …, 2023 - ACS Publications
Coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome-
coronavirus-2 (SARS-CoV-2) which was identified in Wuhan, China in December 2019 and …
coronavirus-2 (SARS-CoV-2) which was identified in Wuhan, China in December 2019 and …
Determining available strategies for prevention and therapy: Exploring COVID‑19 from the perspective of ACE2
L Cai, X Guo, Y Cao, P Ying… - International …, 2021 - spandidos-publications.com
Abstract Coronavirus disease 2019 (COVID‑19) is an acute infectious pneumonia caused by
a novel type of coronavirus infection. There are currently no clinically available specific …
a novel type of coronavirus infection. There are currently no clinically available specific …
Renin-angiotensin system at the interface of COVID-19 infection
Abstract Angiotensin-converting enzyme 2 (ACE2) has been recognized as a potential entry
receptor for SARS-CoV-2 infection. Binding of SARS-CoV-2 to ACE2 allows engagement …
receptor for SARS-CoV-2 infection. Binding of SARS-CoV-2 to ACE2 allows engagement …
The Impact of Angiotensin-Converting Enzyme 2 (ACE2) Expression Levels in Patients with Comorbidities on COVID-19 Severity: A Comprehensive Review
R Rodrigues, S Costa de Oliveira - Microorganisms, 2021 - mdpi.com
Angiotensin-Converting Enzyme 2 (ACE2) has been proved to be the main host cell receptor
for the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the …
for the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the …
[HTML][HTML] RAAS, ACE2 and COVID-19; a mechanistic review
The use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor
blockers (ARBs) in coronavirus disease 2019 (COVID-19) patients has been claimed as …
blockers (ARBs) in coronavirus disease 2019 (COVID-19) patients has been claimed as …
Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety
The COVID-19 pandemic is caused by the severe acute-respiratory-syndrome-coronavirus-2
that uses ACE2 as its receptor. Drugs that raise serum/tissue ACE2 levels include ACE …
that uses ACE2 as its receptor. Drugs that raise serum/tissue ACE2 levels include ACE …